Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
9785-CL-3021

A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma

Astellas Study ID
9785-CL-3021
Clinicaltrials.gov ID
NCT02528643
EUCTIS ID
N/A
EudraCT ID
2014-004283-37
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS).

This study also evaluated the safety of enzalutamide; pharmacokinetics of enzalutamide and the active metabolite N-desmethyl and Progression Free Survival (PFS) of enzalutamide as compared to placebo in participants with advanced HCC.

Additional Study Details

Phase
Phase 2
Product
Enzalutamide
Placebo
Type
Interventional
Masking
Double (Participant, Investigator)
Enrollment number
165
Show Additional Study Details

Study documents

Scientific Results Summary 2
Available Language(s): English
Download Document(s)
Plain Language Summary
Available Language(s): English
Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site KR82004
    Seoul, Republic of Korea, 05505
    Contact Us
    Completed
    Site US10017
    Minneapolis, MN, United States, 55455-0362
    Contact Us
    Completed
    Site KR82002
    Seongnam-Si, Gyeonggi-do, Republic of Korea, 013620
    Contact Us
    Withdrawn
    Site ES34002
    Santiago de Compostela, Spain, 15706
    Contact Us
    Completed
    Site TW88605
    Tainan, Taiwan, Province of China, 710
    Contact Us
    Completed
    Site IT39004
    Pavia, Italy, 27100
    Contact Us
    Completed
    Site US10008
    Portland, OR, United States, 97239
    Contact Us
    Completed
    Site GB44007
    Birmingham, United Kingdom, B15 2WB
    Contact Us
    Completed
    Site ES34006
    Cordoba, Cordoba, Spain, 14004
    Contact Us
    Completed
    Site US10003
    San Francisco, CA, United States, 94115
    Contact Us
    Withdrawn
    Site US10002
    Spartanburg, SC, United States, 29303
    Contact Us
    Completed
    Site ES34003
    Barcelona, Barcelona, Spain, 08035
    Contact Us
    Withdrawn
    Site IT39001
    Napoli, Italy, 80131
    Contact Us
    Completed
    Site CA15001
    Toronto, ON, Canada, M5G2C4
    Contact Us
    Completed
    Site CA15002
    Montreal, QC, Canada, H3T 1E2
    Contact Us
    Completed
    Site KR82006
    Seoul, Republic of Korea, 03080
    Contact Us
    Completed
    Site US10009
    Skokie, IL, United States, 60077
    Contact Us
    Completed
    Site IT39005
    Benevento, Italy
    Contact Us
    Withdrawn
    Site US10015
    Nashville, TN, United States, 37208
    Contact Us
    Completed
    Site IT39002
    Milan, Italy, 20132
    Contact Us
    Withdrawn
    Site US10011
    St. Louis, MO, United States, 63104
    Contact Us
    Completed
    Site ES34004
    Madrid, Spain, 28222
    Contact Us
    Completed
    Site US10001
    San Juan, PR, United States, 00927
    Contact Us
    Completed
    Site US10021
    Lebanon, NH, United States, 03756-1000
    Contact Us
    Completed
    Site GB44008
    London, United Kingdom, W12 OHS
    Contact Us
    Withdrawn
    Site US10022
    San Antonio, TX, United States, 78215-1639
    Contact Us
    Withdrawn
    Site US10010
    Columbus, OH, United States, 43210
    Contact Us
    Completed
    Site GB44005
    Manchester, United Kingdom, M20 4BX
    Contact Us
    Completed
    Site US10019
    Philadelphia, PA, United States, 19104
    Contact Us
    Withdrawn
    Site US10020
    Evanston, IL, United States, 60201
    Contact Us
    Completed
    Site IT39008
    Rozzano, Milan, Italy, 20089
    Contact Us
    Completed
    Site HK85204
    Shatin, Hong Kong, 999077
    Contact Us
    Completed
    Site CA15003
    Montreal, Canada, H4A 3J1
    Contact Us
    Completed
    Site IT39006
    Milano, Italy, 20122
    Contact Us
    Completed
    Site US10014
    Philadelphia, PA, United States, 19104
    Contact Us
    Withdrawn
    Site HK85205
    Tuen Mun, Hong Kong, 999077
    Contact Us
    Terminated
    Site US10016
    Milwaukee, WI, United States, 53226-3522
    Contact Us
    Completed
    Site TW88603
    Douliu, Taiwan, Province of China, 640
    Contact Us
    Completed
    Site HK85202
    Kowloon, Hong Kong, 999077
    Contact Us
    Completed
    Site TW88604
    Taipei City, Taiwan, Province of China, 10048
    Contact Us
    Completed
    Site GB44004
    London, United Kingdom, SE5 9RS
    Contact Us
    Completed
    Site GB44002
    Wirral, United Kingdom, CH63 4JY
    Contact Us
    Completed
    Site KR82001
    Seoul, Republic of Korea, 06591
    Contact Us
    Completed
    Site KR82007
    Seoul, Republic of Korea, 03722
    Contact Us
    Completed
    Site IT39011
    Padova, Italy, 35128
    Contact Us
    Completed
    Site TW88606
    Tainan, Taiwan, Province of China, 704
    Contact Us
    Completed
    Site KR82005
    Seoul, Seoul Teugbyeolsi, Republic of Korea, 135-710
    Contact Us
    Trial info
    Follow Trial
    Age
    18+ years
    Diamond icon
    Condition
  • Liver Cancer
    • Gender icon
    Sex
    Female & Male
    Calendar icon
    Trial Dates
    Nov 2015 - Oct 2017
    Additional Study Details
    Inclusion Criteria
    • Subject is ≥ 18 years of age or is considered an adult according to local regulation at the time of signing informed consent.
    • Subject has a documented diagnosis of advanced HCC of any etiology.
    • Subject has BCLC stage B or C.
    • Subject’s lesions are not amenable to local therapies which may be beneficial, such as transarterial chemoembolization (TACE), radiofrequency ablation, radiotherapy, etc., and the subject is not a candidate for any curative treatments such as resection or liver transplant.
    • Subject has hepatic function status of Child Pugh Class A at Screening.
    • Subject received prior systemic treatment for HCC with sorafenib or other anti-VEGF therapy and had confirmed disease progression or discontinued treatment due to a drug-related toxicity. Subject may have received 1 line of systemic therapy before or after sorafenib/anti-VEGF treatment.
    • Subject has adequately recovered from toxicities due to prior HCC therapy to ≤ grade 1.
    • Subject has an ECOG performance status ≤ 1 at Screening and on Day 1.
    • Subject has available formalin-fixed, paraffin-embedded tumor specimen with adequate viable tumor cells in a tissue block or unstained serial slides accompanied by an associated pathology report prior to enrollment. Archival or fresh biopsy tissue is required.
    • Subject has an estimated life expectancy of at least 3 months on Day 1, in the opinion of the investigator.
    • Female subject is either:
      • Not of childbearing potential: postmenopausal (defined as no spontaneous menses for at least 12 consecutive months prior to Screening with follicle-stimulating hormone [FSH] > 40 IU/L for women < 55 years of age at Screening), or documented to be surgically sterile or status posthysterectomy (at least 1 month prior to Screening).
      • Or, if of childbearing potential: must have a negative urine pregnancy test at Screening and on Day 1 before the first dose of study drug is administered, and must use 2 acceptable methods of birth control* if sexually active from Screening through 3 months after the last dose of study drug.
    • Sexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control from Screening through 3 months after the last dose of study drug.

      • * Two acceptable methods of birth control are as follows:

    • Condom (barrier method of contraception); AND
    • One of the following is required: Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female subject or female partner of a male subject; Additional barrier method: contraceptive sponge or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female subject or female partner of a male subject. For male subject or male partner of female subject, vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy) performed at least 6 months before Screening. Tubal ligation in the female partner of a male subject performed at least 6 months before Screening. Established and ongoing use of oral, injected, or implanted hormonal contraceptive by female partner of a male subject.
    • Female subject must not be breastfeeding at Screening or during the study period and for 3 months after final study drug administration.
    • Subject must agree not to donate sperm or ova from first dose of study drug through 3 months after the last dose of study drug.
    • Throughout the study, male subject must use a condom if having sex with a pregnant woman.
    • Subject must be able to swallow study drug and comply with study requirements.
    • Subject agrees not to participate in another interventional study while on treatment.
    • Received double-blind enzalutamide study treatment during the main study.
    MaximizeExclusion Criteria
    • Subject has a severe concurrent disease, infection or comorbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment.
    • Subject has fibrolamellar variant of HCC.
    • Subject has status of Child-Pugh Class B or C at Screening.
    • Subject has a history of organ allograft including liver transplant.
    • Subject has uncontrolled symptomatic ascites.
    • Subject has known or suspected brain metastasis or active leptomeningeal disease.
    • Subject has a history of a non-HCC malignancy with the following exceptions:
      • The subject with a previous history of a noninvasive carcinoma is eligible if in the opinion of the investigator he/she has had successful curative treatment any time prior to Screening and requires no further therapy for the malignancy.
      • For all other malignancies, the subject is eligible if he/she has undergone potentially curative therapy and has been considered disease free for at least 3 years prior to Screening.
    • Subject has inadequate marrow, hepatic, and/or renal function at the Screening Visit defined as:
      • Absolute neutrophil count < 1.5 x109/L (< 1500 cells/mm3)
      • Platelet count < 50 x109/L (< 50,000 cells/mm3)
      • Hemoglobin < 8.5 g/dL (< 5.3 mmol/L)
      • International normalized ratio > 1.7
      • Albumin < 2.8 g/dL (< 28 g/L)
      • Total bilirubin (TBL) > 2 x ULN
      • AST or ALT > 5 x ULN
      • Creatinine > 1.5 x ULN
      • Note: Transfusions/infusions to meet eligibility criteria are not allowed but if in the opinion of the Principal Investigator, it is beneficial, the patient may be rescreened after receiving one of these procedures.
    • Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma, encephalopathy within 3 months of Day 1).
    • Subject has a history of bleeding esophageal varices within 3 months before the Day 1 visit.
    • Subject has a history of loss of consciousness or transient ischemic attack within 12 months before the Day 1 visit.
    • Subject has clinically significant cardiovascular disease including:
      • Myocardial infarction within 6 months before the Day 1 visit.
      • Uncontrolled angina within 6 months before the Day 1 visit.
      • Congestive heart failure New York Heart Association (NYHA) Class III or IV or history of congestive heart failure NYHA Class III or IV in the past, unless a Screening echocardiogram or multi-gated acquisition scan performed within 3 months before the Day 1 visit reveals a left ventricular ejection fraction that is ≥ 45%.
      • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsade de Pointes).
      • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place.
      • Hypotension as indicated by systolic blood pressure < 86 mmHg on 2 consecutive measurements at the Screening visit.
      • Bradycardia (in the presence of known cardiovascular disease) as indicated by a heart rate of < 50 beats per minute on the Screening electrocardiogram (ECG) recording.
      • Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg on 2 consecutive measurements at the Screening visit.
    • Subject has a gastrointestinal disorder affecting absorption.
    • Subject had previous local therapy (e.g., surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) within 14 days prior to Day 1, has not recovered from toxicities from prior local therapy or may require major surgical procedure during the course of the study.
    • Subject has received chemotherapy, immunotherapy or any other systemic anticancer therapy (including sorafenib) or any other investigational drug within 14 days prior to the Day 1 visit.
    • Subject has received an agent that either blocks androgen synthesis or targets the AR (e.g., abiraterone acetate, bicalutamide, enzalutamide, ARN-509 or other investigational AR signaling inhibitors). The exception of spironolactone is allowed after Medical Monitor consultation.
    • Subject has used any of the following within 28 days before the Day 1 visit:
      • 5-α reductase inhibitors
      • Systemic androgens and estrogens (vaginal estrogen creams are allowed)
      • Herbal therapies, with an antitumor effect.
    • Subject has a known history of positive test for Human Immunodeficiency Virus.
    • Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the enzalutamide capsule components, including caprylocaproyl polyoxylglycerides (Labrasol), butylated hydroxyanisole and butylated hydroxytoluene.
    • Subject has addictive/substance abuse problems.
    • Subject has any other condition or reason that, in the opinion of the investigator, interferes with the ability of the subject to participate in the trial, places the subject at undue risk or complicates the interpretation of safety data.
    • Received double-blind placebo during the main study.

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    Find a Trial
    2

    Why are Clinical Trials Important?

    Learn More
    3

    Why Participate in a Clinical Trial?

    Discover More

    For Your Information

    THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE